The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.
Bronze - Firms: litigation
Highly-recommended - Firms: transactions
Steadfast in its commitment to quality and obtaining the best possible outcomes for its clientele, Sullivan & Cromwell is the first port of call for some of the world’s most innovative companies, thanks to its work on the leading edge of technology transactions and its glittering track record in closing highly complex deals. The names to note in New York are Garrard Beeney, Dustin Guzior, Mehdi Ansari and John Evangelakos. Beeney and Guzior are both co-chairs of the IP and technology litigation group and work closely together on a number of key cases. In the past year, the pair secured a unanimous verdict on behalf of Columbia University, following a two-week jury trial. They are also currently representing the Ocado Group in multiple patent and anti-trust litigations. Ansari is another IP and technology litigation co-chair, having been promoted to this role in 2022. He has a diverse set of patrons that range from healthcare companies to financial organisations. Evangelakos works on a variety of IP- related transactions. He is currently advising BlackBerry regarding its patent sale agreement with Catapult IP Innovations.
Recommended - Firms: transactions
Highly-recommended - Firms: transactions
Sullivan & Cromwell is steadfast in its commitment to quality and obtaining the best possible outcome for its clientele. The outfit is the first port of call for some of the world’s most innovative companies, thanks to its work on the leading edge of technology transactions and its glittering track record in closing highly complex deals. Co-head of the IP and technology group, Nader Mousavi stands out as a creative problem solver who never falters under pressure. He is hands on, honest, transparent, and able to assess risks and opportunities in their entirety to get client-driven deals done. His exceptional transactional capabilities have been put to good use on behalf of BlackBerry, which he has been representing in its patent sale agreement with Catapult IP Innovations, in which BlackBerry will sell substantially all of its non-core patent assets for a total purchase price of $600 million. Shepherding high-value IP-rich deals to a successful close, Mark Schenkel puts in an extraordinary effort to ensure his patrons are successful. Recently, he has teamed up with Mousavi to represent Sumitovant Biopharma in its collaboration with Pfizer, in which the parties will work together to develop and commercialise Sumitovant’s ORGOVYXTM and equally share profits and certain expenses.
Jurisdiction